

BRIEF REPORT

Clinical Utility of Curcumin Extract

Gary N. Asher, MD, MPH; Kevin Spelman, PhD

ABSTRACT

Turmeric root has been used medicinally in China and India for thousands of years. The active components are thought to be the curcuminoids, primarily curcumin, which is commonly available worldwide as a standardized extract. This article reviews the pharmacology of curcuminoids, their use and efficacy, potential adverse effects, and dosage and standardization. Preclinical studies point to mechanisms of action that are predominantly anti-inflammatory and antineoplastic, while early human clinical trials suggest beneficial effects for dyspepsia,

peptic ulcer, inflammatory bowel disease, rheumatoid arthritis, osteoarthritis, uveitis, orbital pseudotumor, and pancreatic cancer. Curcumin is well-tolerated; the most common side effects are nausea and diarrhea. Theoretical interactions exist due to purported effects on metabolic enzymes and transport proteins, but clinical reports do not support any meaningful interactions. Nonetheless, caution, especially with chemotherapy agents, is advised. Late-phase clinical trials are still needed to confirm most beneficial effects. (*Altern Ther Health Med.* 2013;19(2):20-22.)

Gary N. Asher, MD, MPH, is assistant professor in the Department of Family Medicine, University of North Carolina, Chapel Hill, North Carolina. **Kevin Spelman, PhD**, is adjunct assistant professor at Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts; distinguished lecturer at Tai Sophia Institute, Laurel, Maryland; and chief scientific officer at the Research and Development Laboratory, Herb Pharm, Williams, Oregon.

Corresponding author: Gary Asher, MD, MPH
E-mail address: gasher@med.unc.edu

Turmeric (*Curcuma longa*) is a perennial shrub native to southern Asia and cultivated extensively throughout Asia and Africa. The yellowish root is dried and powdered to yield a commercially available spice that is used worldwide and gives curry its characteristic yellow color.¹ *C longa* is a member of the ginger family (Zingiberaceae) that has been used in the ancient medicinal traditions of India and China for thousands of years. In 2010, sales of *C longa* in the United States exceeded \$11 million, an increase of over 10% from the previous year, making it the fourth most popularly sold botanical in the United States.²

Curcumin is the fraction of the root that gives turmeric its color and is commonly used as a flavoring, additive, preservative, and coloring agent that is considered nontoxic.³

Capsules containing curcumin extract are widely available commercially around the world.

A number of recent reviews have summarized the extensive literature on the mechanisms of curcumin's purported effects. A wide range of preclinical evidence suggests that curcumin has a diverse range of molecular targets and acts both directly with proteins and indirectly through modulation of gene expression. Curcumin has been reported to be anti-inflammatory, antioxidant, antineoplastic, proapoptotic, antiangiogenic, cytotoxic, immunomodulatory, and antimicrobial, with the ability to modulate numerous targets, including growth factors and growth-factor receptors, transcription factors, cytokines, enzymes, and genes regulating cell proliferation and apoptosis.⁴⁻⁶

PHARMACOLOGY

The major constituents of turmeric roots are the volatile oils and the curcuminoids (ie, curcumin, demethoxycurcumin, and bisdemethoxycurcumin). Typical curcumin extracts available commercially contain about 75% curcumin, 20% demethoxycurcumin, and 5% bisdemethoxycurcumin, all of which are thought to be primarily responsible for the extracts' pharmacologic effects.³

The majority of studies on curcumin extracts are in vitro and animal studies. Anti-inflammatory and tumor-regulatory properties of curcumin are attributed to its effects at multiple targets, including NFκB, AP-1, Nrf2, JNK, COX-2, PPAR-α, cyclin D1, EGFR, p53, procaspases, bcl-2, and VEGF.⁴⁻⁶

Table 1. Key Points About Curcumin

Effectiveness	May be beneficial for inflammatory and malignant disorders, including rheumatoid arthritis, osteoarthritis, uveitis, orbital pseudotumor, a variety of premalignant or preinvasive malignancies, familial adenomatous polyposis, and dyspepsia.
Adverse Effects (AE).	Is “Generally Regarded as Safe” (GRAS) by the FDA; observed AEs include diarrhea, nausea, and increased frequency in bowel movements (resolving spontaneously after 1-3 days).
Interactions.	No interactions with prescription drugs have been observed; has known effects with cytochrome P450 1A1, 1A2, 3A4, 2B6, 2C9, 2D6, glutathione S-transferase, and P-glycoprotein.
Contraindications.	Has potential to trigger biliary colic in individuals with gallstones.
Dosage.	Most effective dosage is currently unknown; recommended dosages range from 1000-8000 mg per day in 1-3 divided doses.
Cost.	Is \$6.50-\$12.00 per month, based on a 1200-1800 mg daily dosage.
Bottom Line.	Curcumin appears to be well-tolerated and safe for general use; may be effective for a wide variety of conditions, including gastrointestinal diseases, such as dyspepsia, and some cancers; evidence from late-phase clinical trials is needed before confident recommendations can be made.

Although in vitro studies show curcumin to be a potential chemotherapeutic agent against a broad range of cancer cells, its advance toward clinical use has been hindered by its short half-life and low bioavailability after oral administration.⁷

POTENTIAL USES AND EFFICACY

A number of early-phase clinical studies provide evidence that curcumin may be beneficial for inflammatory and malignant disorders. Although these early trials often emphasized pharmacokinetics and safety, beneficial effects of curcumin have been demonstrated for dyspepsia,⁸ osteoarthritis,⁹ rheumatoid arthritis,¹⁰ uveitis,¹¹ orbital pseudotumor,¹ a variety of premalignant or preinvasive malignancies,¹³ familial adenomatous polyposis,¹⁴ inflammatory bowel disease,¹⁵ and pancreatic cancer.¹⁶

Other uses may include treatment of chronic neurodegenerative conditions because curcumin has shown protective abilities against neurotoxic and genotoxic agents. For example, in the case of Alzheimer’s disease, curcumin has shown disaggregation of amyloid-β peptide. Other activities include inhibition of NFκB, prevention of fibril and oligomer formation, inhibition of Egr-1, amyloid-β peptide cell death, and activation of transcription factors.¹⁷

CONTRAINDICATIONS, ADVERSE EFFECTS, AND INTERACTIONS

Due to their ability to increase bile secretion, turmeric extracts have the potential to trigger biliary colic in predisposed individuals with gallstones.¹⁸ Therefore, patients with cholelithiasis should avoid turmeric or curcumin extracts.

Turmeric is on the FDA’s “Generally Regarded as Safe” (GRAS) list. Curcumin doses up to 8 g daily have been administered for several months of treatment in clinical trials without serious adverse events. Only a few clinical studies

of oral curcumin and curcuminoids have reported perceptible side effects at doses ranging from 180 mg to 12 g.¹⁹ In the few cases where side effects have been observed, those effects have mainly involved gastrointestinal discomfort, which may have been due to underlying symptoms. Two types of gastrointestinal side effects, diarrhea and nausea, have been most commonly reported, and they are probably related to curcumin consumption. Increased frequency in bowel movements has been observed in clinical trials. The diarrhea, however, does not appear to be dose-related and resolves spontaneously after 1 to 3 days regardless of whether the curcumin is discontinued.²⁰

Based on in vitro and animal models, several potential drug interactions exist. Curcumin has known effects on a variety of metabolic enzymes, such as cytochrome P450 (CYP) 1A1, 1A2, 3A4, 2B6, 2C9, 2D6, and glutathione S-transferase, as well as on the efflux pump, P-glycoprotein.²¹⁻²³ Because curcumin also has effects at a large number of molecular targets associated with tumor initiation and progression, it is possible that curcumin may alter the efficacy of some chemotherapy agents. Until there is better understanding of the effects of curcumin on chemotherapy agents, use of curcumin during cancer chemotherapy is not recommended. However, no interactions with prescription drugs have been observed in individual patients or during human clinical trials.²⁴

TOXICOLOGY

In animal studies, no acute or chronic toxicity has been shown, even at high doses. Likewise, mutagenicity and reproductive toxicity have not been observed in rodents.²⁵⁻²⁷

In humans, several studies have demonstrated minimal toxicity with moderate doses of curcumin. Even at doses as high as 12 g, curcumin is not associated with increases in adverse events over placebo.^{28,29}

USE IN PREGNANCY

Turmeric has been used during pregnancy in a variety of traditional medical systems for thousands of years, and no traditional or Western authority recommends against its use during pregnancy.^{30,31} The isolated curcuminoids, although apparently safe in rodents, are less well understood in humans. Therefore, for use during pregnancy or breastfeeding, consultation with a clinician who has expertise in phytotherapy is advised.³

DOSAGE AND STANDARDIZATION

A common, therapeutic curcumin dose is 400 to 600 mg three times daily, corresponding to 60 g of fresh turmeric root or about 15 g of turmeric powder. In clinical cancer trials, doses of 4 to 8 g per day of curcumin are typical. Because curcumin is poorly absorbed into the blood stream, several proprietary formulations purport to increase its bioavailability via lipid complexes or nanoparticle formulations. Lower doses of these special preparations may be equivalent to higher doses of standard powder, but further study is needed to confirm the effect.³² Other strategies to increase curcumin absorption include coadministration of the naturally occurring volatile oils from turmeric root, or piperine, a product from black pepper.³³

While turmeric and curcumin powders are uncommonly adulterated, some concern exists that lead may contaminate some batches of prepared supplements.³⁴ For that reason, it is recommended to purchase curcumin supplements only from US manufacturers that follow recommended Good Manufacturing Practices (GMP), which require testing for heavy metals.

BOTTOM LINE

Turmeric and curcumin supplements appear to be well-tolerated and safe for general use. Preclinical and early clinical trials provide some evidence of efficacy for a wide variety of conditions including gastrointestinal diseases, such as dyspepsia, and some cancers. Evidence from late-phase clinical trials is needed, however, before a confident recommendation for or against its use can be made.

ACKNOWLEDGEMENTS

This project was supported by award number UL1RR025747 from the National Center for Research Resources (GNA).

REFERENCES

- Bruneton J. *Pharmacognosy, Phytochemistry, Medicinal Plants*. 2nd ed. Paris, France: Lavoisier; 1999.
- Blumenthal M, Lindstrom A, Lynch ME, Rea P. Herb sales continue growth—up 3.3% in 2010. *HerbalGram*. Summer 2011;(90):64-67.
- European Scientific Cooperative on Phytotherapy. *ESCO Monographs: The Scientific Foundation for Herbal Medicinal Products*. Exeter, UK: Thieme; 2003.
- Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. *Arch Physiol Biochem*. 2008;114(2):127-149.
- Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. *Antioxid Redox Signal*. 2008;10(3):511-545.
- Villegas I, Sanchez-Fidalgo S, Alarcon de la Lastra C. New mechanisms and therapeutic potential of curcumin for colorectal cancer. *Mol Nutr Food Res*. 2008;52(9):1040-1061.
- Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. *Mol Pharm*. 2007;4(6):807-818.
- Thamlikitkul V, Bunyapraphatsara N, Dechatiwongse T, et al. Randomized double blind study of *Curcuma domestica* Val. for dyspepsia. *J Med Assoc Thai*. 1989;72(11):613-620.
- Belcaro G, Cesarone MR, Dugall M, et al. Product-evaluation registry of Meriva(R), a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. *Paininerva Med*. 2010;52(2)(suppl 1):55-62.
- Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). *Indian J Med Res*. Apr 1980;71:632-634.
- Allegrì P, Mastromarino A, Neri P. Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment: long-term follow-up. *Clin Ophthalmol*. Oct 2010;4:1201-1206.
- Lal B, Kapoor AK, Agrawal PK, Asthana OP, Srimal RC. Role of curcumin in idiopathic inflammatory orbital pseudotumours. *Phytother Res*. 2000;14(6):443-447.
- Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. *Anticancer Res*. 2001;21(4B):2895-2900.
- Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. *Clin Gastroenterol Hepatol*. 2006;4(8):1035-1038.
- Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. *Dig Dis Sci*. 2005;50(11):2191-2193.
- Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. *Clin Cancer Res*. 2008;14(14):4491-4499.
- Kannappan R, Gupta SC, Kim JH, Reuter S, Aggarwal BB. Neuroprotection by spice-derived nutraceuticals: you are what you eat! *Mol Neurobiol*. 2011;44(2):142-159.
- Teuscher E, Bauermann U, Werner M. Turmeric. In: Teuscher E, Bauermann U, Werner M, eds. *Medicinal Spices: A Handbook of Culinary Herbs, Spices, Spice Mixtures and Their Essential Oils*. Stuttgart: Medpharm Scientific Publishers Stuttgart; 2006:404-410.
- Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. *Cell Mol Life Sci*. 2008;65(11):1631-1652.
- Sharma RA, Euden SA, Platon SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. *Clin Cancer Res*. 2004;10(20):6847-6854.
- Appiah-Opong R, Commandeur JN, van Vugt-Lussenburg B, Vermeulen NP. Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. *Toxicology*. 2007;235(1-2):83-91.
- Oetari S, Sudibyo M, Commandeur JN, Samhoedi R, Vermeulen NP. Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver. *Biochem Pharmacol*. 1996;51(1):39-45.
- Hou XL, Takahashi K, Tanaka K, et al. Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways. *Int J Pharm*. 2008;358(1-2):224-229.
- Stargrove MB, Treasure J, McKee DL. Turmeric/Curcumin (*Curcuma longa*). In: *Herb, Nutrient, and Drug Interactions: Clinical Implications and Therapeutic Strategies*. St Louis, MO: Mosby; 2007:160-166.
- Azuine MA, Kayal JJ, Bhide SV. Protective role of aqueous turmeric extract against mutagenicity of direct-acting carcinogens as well as benzo [alpha] pyrene-induced genotoxicity and carcinogenicity. *J Cancer Res Clin Oncol*. 1992;118(6):447-452.
- Jensen NJ. Lack of mutagenic effect of turmeric oleoresin and curcumin in the Salmonella/mammalian microsome test. *Mutat Res*. 1982;105(6):393-396.
- Vijayalaxmi. Genetic effects of turmeric and curcumin in mice and rats. *Mutat Res*. 1980;79(2):125-132.
- Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (*Curcuma longa*). *J Altern Complement Med*. 2003;9(1):161-168.
- Lao CD, Ruffin MT IV, Normolle D, et al. Dose escalation of a curcuminoid formulation. *BMC Complement Altern Med*. Mar 2006;6:10.
- Blumenthal M, Goldberg A, Brinckmann J, eds. *Herbal Medicine: Expanded Commission E Monographs*. Newton, MA: Integrative Medicine Communications; 2000.
- Mills S, Bone K. Turmeric. *The Essential Guide to Herbal Safety*. St Louis, MO: Churchill Livingstone; 2005.
- Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. *J Nat Prod*. 2011;74(4):664-669.
- Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Med*. 1998;64(4):353-356.
- Saper RB, Kales SN, Paquin J, et al. Heavy metal content of ayurvedic herbal medicine products. *JAMA*. 2004; 292(23): 2868-2873.